What DSIP (Delta Sleep-Inducing Peptide) is

DSIP (Delta Sleep-Inducing Peptide) belongs to the family of CNS-active research peptides — short, blood-brain-barrier-permeable sequences originally developed in Russian neurology laboratories (Selank, Semax) or endogenously identified in mammalian sleep-EEG research (DSIP). The class has produced a small but consistent body of published data on anxiolytic, nootropic, and sleep-modulating endpoints.

DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide originally isolated from rabbit cerebral venous blood during delta-wave sleep in the Monnier and Schoenenberger experiments (1970s).

Mechanism of action

• Selank modulates GABAergic and serotonergic transmission, upregulates BDNF and NGF expression, and increases enkephalin activity via inhibition of enkephalinase. Human EEG studies report a shift toward alpha-wave dominance.
• Semax upregulates BDNF within 15–30 minutes of intranasal administration and modulates dopaminergic, serotonergic, and cholinergic systems. It also has documented effects on the melanocortin system (via its ACTH-derived sequence).
• DSIP modulates delta-wave sleep EEG signatures and appears to influence corticotropin-releasing factor, though its full mechanism remains incompletely characterized.

Published research findings

• Selank has published Russian clinical data in generalized anxiety disorder, with results reported comparable to benzodiazepine anxiolytics without the sedation, dependence, or cognitive-impairment profile.
• Semax has published data in cerebral-ischemia recovery, optic-nerve atrophy, and cognitive-performance endpoints.
• DSIP has been studied in insomnia, chronic pain, and opioid-withdrawal protocols.

Routes reported in research

• Intranasal dominates in this class. The nasal mucosa provides direct access to the CNS via olfactory and trigeminal pathways, bypassing hepatic first-pass metabolism and the blood-brain barrier. Bioavailability from nasal delivery is substantially higher than oral for these compounds.
• Subcutaneous injection is a secondary route used in some protocols.

Dosing ranges reported in the literature

• Selank: 250–500 µg per nostril, 1–3 times daily, delivered as a saline nasal spray.
• Semax: 300–600 µg per nostril, 1–2 times daily. Higher-concentration "0.1%" formulations exist in Russian clinical use.
• DSIP: 100–500 µg subcutaneous, typically dosed 30–60 minutes pre-sleep.

Onset and duration

Selank and Semax are absorbed within minutes intranasally; subjective and BDNF-marker effects peak inside the first hour. Both are cleared within hours despite functional CNS effects that outlast plasma exposure. DSIP effects on sleep architecture are typically observed the same night as dosing.

Stacking discussed in the literature

• Selank + Semax — the canonical nootropic pairing.
• DSIP + magnesium/GABA-support — for research protocols focused on sleep architecture.
• Semax + Cerebrolysin — in neuroprotection/recovery protocols.

Standard laboratory handling

Every research vial from PX1 is a lyophilized (freeze-dried) powder sealed under vacuum in a Type-I borosilicate vial with a butyl-rubber stopper and aluminum crimp seal. Correct handling preserves potency and prevents peptide-bond hydrolysis that degrades the active molecule.

• Storage before reconstitution: 2–8 °C refrigerator is ideal; freezer (−20 °C) for storage beyond six months. Short excursions to room temperature during shipping do not compromise integrity — the compound is stable in its solid state.
• Reconstitution solvent: bacteriostatic water for injection (0.9% benzyl alcohol) is standard for research protocols that require multiple sampling events from the same vial. Sterile water is acceptable for single-use protocols.
• Reconstitution technique: inject the diluent slowly against the vial wall — never directly onto the lyophilized cake. Swirl gently; do not shake. Shaking introduces air, denatures peptide secondary structure, and can create insoluble aggregates.
• Post-reconstitution storage: 2–8 °C refrigerated, typically stable 21–30 days depending on the peptide. Freezing a reconstituted solution repeatedly is not recommended — freeze/thaw cycles are the single biggest driver of loss-of-potency in the research literature.
• Concentration math: volume of diluent (mL) = peptide mass (mg) ÷ desired concentration (mg/mL). Example: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL.

Purity, identity and COA verification

The single most important due-diligence step when sourcing DSIP (Delta Sleep-Inducing Peptide) for research is reviewing the lot-specific Certificate of Analysis (COA). A credible COA contains:

1. HPLC purity value with chromatogram — target ≥ 98% for injectable-grade research peptides; ≥ 99% for the newest generation of GLP/incretin compounds. A single well-defined main peak with baseline separation from impurities is what you are looking for.
2. Identity confirmation by mass spectrometry — LC-MS or MALDI-TOF confirming the observed molecular weight matches the theoretical mass to within instrument tolerance.
3. Endotoxin (LAL / kinetic-chromogenic) result — expressed in EU/mg; USP guidance for parenteral products is well below 5 EU/kg body-weight equivalent, and reputable suppliers report < 10 EU/mg on the COA.
4. Sterility result — USP <71> membrane filtration or direct inoculation, both bacterial and fungal.
5. Karl Fischer moisture — target < 5% residual water for a properly lyophilized cake.
6. Residual-solvent screen — DMF, TFA, DCM, acetonitrile below ICH Q3C thresholds.

PX1 publishes lot-specific COAs at /purity-reports. If you have received a shipment and want to verify the exact lot documentation for DSIP (Delta Sleep-Inducing Peptide), cross-reference the lot number on the vial label to the COA PDF.

Why researchers choose PX1 for DSIP (Delta Sleep-Inducing Peptide)

• 100% U.S. synthesis, lyophilization, and fill/finish. No repackaged imports. Every step from raw amino acid to sealed vial happens under one U.S. GMP-compliant roof.
• Third-party ISO-17025 testing on every lot. Purity, identity, endotoxin, sterility, moisture, and residual-solvent testing performed by an independent analytical laboratory whose data appears on the shipped COA.
• Chain-of-custody documentation from raw material through final QC — the same documentation package a clinical CDMO would provide.
• Same-day shipping on in-stock catalog items ordered before 3 p.m. ET, with insulated packaging and cold-pack where appropriate.

Common researcher questions

Q: How do I know the vial contents match the label? Compare the lot number on the vial to the lot number on the COA. The COA lists HPLC purity, identity by mass-spec, and endotoxin. If any of the three is missing or the lot doesn't match, don't proceed.

Q: Can I use bacteriostatic water past its printed expiration? Bacteriostatic water carries a manufacturer-assigned expiration for the sealed vial. Once punctured, USP guidance limits multi-dose vials to 28 days at 2–8 °C. Beyond 28 days, discard.

Q: Is refrigeration required during shipping? For most lyophilized peptides, no — the solid form is stable at ambient temperature for weeks. Some compounds (IGF-1 LR3, certain GH-releasing peptides) benefit from cold-chain shipping. PX1 uses insulated packaging for temperature-sensitive lines.

Q: What if the reconstituted solution is cloudy? Cloudiness indicates aggregation or precipitation and the solution should not be used. Common causes: over-vigorous shaking, incompatible diluent, or a vial that has passed its stability window.

Research use disclaimer

DSIP (Delta Sleep-Inducing Peptide) is supplied to licensed research professionals for in vitro and in vivo laboratory research only. Products are not intended for human consumption, veterinary use, diagnostic use, therapeutic use, or as a food additive or cosmetic. Nothing on this page constitutes medical advice. Consult the primary literature — clinical-trial registrations, peer-reviewed publications — before designing any protocol. Compounds discussed here are investigational; several have not received FDA approval for any indication.

Additional PX1 references

• Complete research library
• Lot-specific purity reports
• Product catalog
• Manufacturing & QC standards